Trial Profile
A Double Blind, Dose Response Phase II, Multicentre Study of Radium 223 (Alpharadin) for the Palliation of Painful Bone Metastases in Hormone Refractory Prostate Cancer Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Jan 2022
Price :
$35
*
At a glance
- Drugs Radium 223 chloride (Primary)
- Indications Adenocarcinoma; Bone metastases; Cancer pain; Prostate cancer
- Focus Therapeutic Use
- Sponsors Bayer
- 17 Dec 2012 New source identified and integrated (German Clinical Trials Register; DRKS00004104).
- 15 Feb 2012 Results published in the European Journal of Cancer.
- 17 Sep 2010 New trial record